Lilly recently announced that the company has launched and sold the best-selling weight loss drug Zepbound in small bottles of 2.5mg and 5mg single dose tirzepatide in the United States to meet the growing demand. Patients can buy the two specifications on Lilly's self operated website "LillyDirect", with monthly fees of $399 and $549 respectively. Compared to the price of all other GLP-1 drugs used to treat obesity, the price of single dose vials can enjoy a 50% or higher discount, and this new option helps millions of obese adults get the medication they need.
A research report shows that although cost reduction may lower the average selling price of Eli Lilly Zepbound in the short term, the additional sales of bottled drugs "may have a positive impact on Eli Lilly's sales performance".
From the current situation, the main market share of GLP-1 drugs worldwide is occupied by Novo Nordisk and Eli Lilly. According to Pfizer's forecast, GLP-1 receptor agonists in the US market alone will generate $50 billion to $55 billion in revenue for weight loss indications by 2030. Considering that the weight loss indication of Tilpotide has been approved for market in November 2023, and that Eli Lilly and Novo Nordisk continue to expand production capacity, Goldman Sachs' analysis team has raised the global weight loss drug market size from $100 billion at the end of last year to $130 billion by 2030.
Recently, Eli Lilly released its financial performance for the second quarter of 2024, which greatly exceeded market expectations. Lilly's revenue for the second quarter was $11.3 billion, a year-on-year increase of 36%. This is mainly due to the contribution of Mu Fengda (Mounjaro – type 2 diabetes indication, Zepbound – long-term weight management indication) and alternative. Excluding the $579 million revenue from the sale of Baqsimi (glucagon nasal powder) equity in Q2 2023, Q2 revenue increased by 46% year-on-year; The revenue of non intestinal glucagon drugs increased by 17% globally and 25% in the United States.